Investments
26Portfolio Exits
4Funds
3About Visionary Venture Fund
Visionary Venture Fund is a venture capital firm that invests in the most promising emerging ophthalmology companies. With many breakthrough ophthalmic technologies and platforms on the horizon, Visionary Venture Fund was created to help these companies by contributing clinical expertise, commercialization know-how, and growth capital.
Latest Visionary Venture Fund News
Nov 7, 2022
Disclosures: Jackson reports consulting for Alcon, Allergan/AbbVie, Bausch + Lomb, Bruder, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Johnson & Johnson, Lensar, Novartis, Ocular Therapeutix, Ocuphire, Rayner/Omeros, RxSight, ScienceBased Health, Sight Sciences, Sun Pharmaceuticals, Trukera, Versea and Visus and being a shareholder in Ace Vision Group, Calhoun Vision, Excelerate Health Fund, Lenticular Research Group, Myze, Ocuphire, Paragon, RPS and Visionary Venture Fund II. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio I would like to congratulate Mitch Jackson on his 100th Premium Channel column in OSN. Mitch’s entertaining approach to presenting cutting-edge techniques and technology in premium refractive surgery has always matched his ebullient personality. Richard L. Lindstrom, MD Source: Healio As premium surgeons, we frequently pass information to one another to better our outcomes, business practices and/or our self-beings as persons as well as surgeons. The term “whisperer,” as in the games “Chinese whispers” or “telephone,” involves the passing of information, but it gets slightly changed each time going from one person to another. In 2011, I started a column called the Fine Art of Premium IOLs in Premier Surgeon, a sister publication to Ocular Surgery News, which carried into 2013, when my first Premium Channel column ran in the practice management section of OSN. Now, we have reached my 100th Premium Channel installment. Mitchell A. Jackson Information has been passed from this one premium surgeon to all my premium surgeon colleagues, but the times have changed and so has the information for the most part, at least in terms of clinical and therapeutic applications. You can scan the accompanying QR code to access my Premium Channel columns, but I am going to highlight my 20 favorite ones — two from each year over the past 10 years. 1. Solving the ‘-osin’ mystery (June 10, 2013) — Thorough preoperative planning is key in avoiding potential IFIS-related complications during and after cataract surgery. 4. Top five fact vs. fiction analysis of femtosecond laser cataract surgery (Dec. 10, 2014) — Dispelling myths may help the premium surgeon decide on whether to add a laser to his or her armamentarium. 5. Does [pupil] size matter? How premium surgeons can avoid the inevitable (Aug. 10, 2015) — When a pupil is at least 5.25 mm or greater at the start of the procedure, the main goal is to prevent intraoperative progressive miosis as the case proceeds. 6. ‘Talking heads’ act as guardians of patient care (Nov. 10, 2015) — These key opinion leaders help improve the lives of patients and fellow practitioners. 7. A little microburst goes a long way (Oct. 10, 2016) — Microburst phaco techniques in conjunction with femtosecond laser-assisted cataract surgery can result in faster surgery with less ultrasound power. 8. 2016 year in review: Miracles do happen (Jan. 10, 2017) — Looking ahead, anticipated approvals for new devices and pharmaceuticals would benefit patients and physicians in 2017. 9. Are bacteria getting smarter? (July 10, 2017) — The premium surgeon has to be prepared to combat bacterial resistance. The beauty of being able to put down my editorial and personal perspective as a premium surgeon for my colleagues, industry and friends has been quite rewarding this past decade. I want to thank the entire Healio/Ocular Surgery News team for all its work to make this Premium Channel column a reality, allowing the “eye whispering” to continue through the years. I look forward to continue bringing my perspective quarterly, with my next column looking back at the top 10 industry moments of 2022. Stay safe and healthy, and thanks to all my followers who read this column. For more information: Mitchell A. Jackson, MD, can be reached at Jacksoneye, 300 N. Milwaukee Ave., Suite L, Lake Villa, IL 60046; email: mjlaserdoc@msn.com . Read more about
Visionary Venture Fund Investments
26 Investments
Visionary Venture Fund has made 26 investments. Their latest investment was in TearClear as part of their Series C on July 7, 2023.

Visionary Venture Fund Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/11/2023 | Series C | TearClear | $11.76M | No | 1 | |
3/8/2023 | Series C | ONL Therapeutics | $15M | Yes | 2 | |
12/29/2022 | Series A - II | Amydis | $6M | Yes | 1 | |
11/30/2022 | Series A | |||||
8/9/2022 | Series B |
Date | 7/11/2023 | 3/8/2023 | 12/29/2022 | 11/30/2022 | 8/9/2022 |
---|---|---|---|---|---|
Round | Series C | Series C | Series A - II | Series A | Series B |
Company | TearClear | ONL Therapeutics | Amydis | ||
Amount | $11.76M | $15M | $6M | ||
New? | No | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 2 | 1 |
Visionary Venture Fund Portfolio Exits
4 Portfolio Exits
Visionary Venture Fund has 4 portfolio exits. Their latest portfolio exit was RxSight on July 30, 2021.
Visionary Venture Fund Fund History
3 Fund Histories
Visionary Venture Fund has 3 funds, including Visionary Venture Fund II (QP).
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/28/2019 | Visionary Venture Fund II (QP) | $46.6M | 1 | ||
6/28/2019 | Visionary Venture Fund II | ||||
5/2/2017 | Visionary Venture Fund |
Closing Date | 6/28/2019 | 6/28/2019 | 5/2/2017 |
---|---|---|---|
Fund | Visionary Venture Fund II (QP) | Visionary Venture Fund II | Visionary Venture Fund |
Fund Type | |||
Status | |||
Amount | $46.6M | ||
Sources | 1 |
Visionary Venture Fund Team
2 Team Members
Visionary Venture Fund has 2 team members, including current Founder, Chief Investment Officer, Managing Partner, Jeffry Weinhuff.
Name | Work History | Title | Status |
---|---|---|---|
Jeffry Weinhuff | Founder, Chief Investment Officer, Managing Partner | Current | |
Name | Jeffry Weinhuff | |
---|---|---|
Work History | ||
Title | Founder, Chief Investment Officer, Managing Partner | |
Status | Current |
Compare Visionary Venture Fund to Competitors
Laureate Pharma is a company focused on the healthcare and pharmaceutical industry. It provides a range of services including the synthesis of pharmaceutical substances, the creation of finished dosage forms, and the development and launch of pulmonary drugs. The company primarily sells to the healthcare sector, with a focus on pharmacies and other pharmaceutical companies. It is based in Princeton, New Jersey.

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.
The Liposome Company is developing liposome-based drug delivery
Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.
Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.
Cytogel, Inc., is working on the development of promising drug candidates and drug delivery technologies
Loading...